Breaking Finance News

Novartis AG (ADR) (NYSE:NVS) has been downgraded to Hold in a statement by TheStreet earlier today.

TheStreet has downgraded Novartis AG (ADR) (NYSE:NVS) to Hold in a statement released on Wednesday September 28, 2016.

Yesterday Novartis AG (ADR) (NYSE:NVS) traded -0.37% lower at $79.25. The company’s 50-day moving average is $80.36 and its 200-day moving average is $78.69. The last stock close price is up 0.34% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 3,635,597 shares of the stock were exchanged, up from an average trading volume of 1,329,330

See Chart Below

Novartis AG (ADR) (NYSE:NVS)

Novartis AG (ADR) has a 52 week low of $69.90 and a 52 week high of $95.11 with a P/E ratio of 28.19 The company’s market cap is currently $0.

In addition to TheStreet reporting its target price, a total of 4 firms have issued a report on the stock. The consensus target price is $94.50 with 2 firms rating the stock a strong buy, 1 firm rating the stock a buy, 1 firm rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

General Information About Novartis AG (ADR) (NYSE:NVS)

Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company's segments include Pharmaceuticals, Alcon and Sandoz. Its Pharmaceuticals segment is engaged in researching, developing, manufacturing, distributing and selling patented prescription medicines in the therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience and established medicines. Its Alcon segment is engaged in developing, manufacturing and selling eye care products across the world. Its Sandoz segment is engaged in developing, manufacturing and marketing generic pharmaceutical products, follow-on biopharmaceutical products known as biosimilars and drug substances that are not protected by valid and enforceable third-party patents.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *